SCHEMBL4660744

SCHEMBL4660744

Oc1cccc2c1CCCN2c1ccnc(Nc2cccc(Cl)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.48
KDR P35968 2/20 0.48
CAMK2D Q13557 5/20 0.46
CDK1 P06493 2/20 0.45
SMG1 Q96Q15 2/20 0.45
ALK Q9UM73 1/20 0.44
MAOB P27338 2/20 0.43
GRM5 P41594 2/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCD Q05655 1/20 0.43
CDK4 P11802 2/20 0.41
MAOA P21397 1/20 0.41
NPC1 O15118 1/20 0.41
CCNT1 O60563 1/20 0.41
MAPT P10636 1/20 0.41
CCNB1 P14635 1/20 0.41
XBP1 P17861 1/20 0.41
CCNA2 P20248 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13911389 0.88 ROCK1 (0.44) CDK2KDRCAMK2DCDK1SMG1
SCHEMBL4659590 0.85 ROCK1 (0.56) CDK2KDRCAMK2DCDK1SMG1
Hydrochloric Acid SCHEMBL4247394 0.84 ROCK1 (0.55) CDK2KDRCAMK2DCDK1SMG1
SCHEMBL4245472 0.84 AIMP2 (0.42) KDRALKABL1BCRPRKCA
SCHEMBL4248784 0.82 KDR (0.48) CDK2KDRSMG1ALKCDK4
SCHEMBL27760699 0.82 ROCK1 (0.38) CDK1SMG1CCNT1CCNB1MTOR
SCHEMBL4245377 0.81 RET (0.39) KDRROCK1
SCHEMBL4244620 0.81 PTK2 (0.52) KDRALKABL1CDK7CDK5
SCHEMBL4252261 0.80 CCNT1 (0.50) CDK2CDK1SMG1CCNT1CCNB1
SCHEMBL4247112 0.79 IKBKB (0.43) CDK2KDRCDK1SMG1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001864-A1 HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA Novartis Pharma AG (CH) 2008-12-17 EP disclosed
WO-2007109045-A1 HETEROCYCLIC ORGANIC COMPOUNDS FOR THE TREATMENT OF IN PARTICULAR MELANOMA NOVARTIS AG (CH) 2007-09-27 WO disclosed